CAMBRIA

NCT03609047 📎

Regimen

Experimental
Camrelizumab 200 mg IV q2w + nab-paclitaxel 125 mg/m2 d1, d8, d15 q4w.
Control
Placebo + nab-paclitaxel 125 mg/m2 d1, d8, d15 q4w.

Population

Previously untreated locally advanced or metastatic triple-negative breast cancer; PD-L1 CPS>=1 required for primary analysis population.

Key finding

Camrelizumab + nab-paclitaxel in 1L PD-L1+ mTNBC. Supports second Chinese PD-1 (after TORCHLIGHT) positive phase 3 in TNBC IO+chemo space. Likely NMPA submission for PD-L1+ mTNBC indication expansion.

Timeline

    Guideline citations

    • NCCN BREAST